Cell and Gene Therapy Manufacturing Services Market to exceed US$ 26,724.90 million by 2030

    Published on 25-Sep-2023
         Request For Sample

    Report : Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 - Global Analysis – by Type [Cell Therapy (Autologous and Allogenic) and Gene Therapy (Viral and non-Viral Vector)], Indication (Cancer, Orthopaedics, and Others), Application (Clinical Manufacturing and Commercial Manufacturing), and End User [Pharmaceutical and Biotechnology Companies and Contract Research Organization (CROs)]

    Cell Therapy Segment Likely to Dominate Cell and Gene Therapy Manufacturing Services Market by Type During 2022–2030[AT1] 

    According to our new research study on "Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 – Global Analysis – by Type, Indication, Application, and End User," the market is expected to reach US$ 26,724.90 million by 2030 from US$ 7,581.97 million in 2022. The market is estimated to register a CAGR of 17.1% from 2022 to 2030. The report highlights the key factors driving the cell and gene therapy manufacturing services market growth and prominent players with their developments in the market. 

    Based on type, the cell and gene therapy manufacturing services market is segmented into cell and gene therapy. The cell therapy segment is further divided into autologous and allogeneic. Further, the gene therapy segment is bifurcated into viral vectors and non-viral vectors. The cell therapy segment held a larger market share in 2022. The gene therapy segment is anticipated to register a higher CAGR during 2022–2030. The growth of the cell therapy segment is attributed to the increasing number of products entering the market; the potential application of cell therapies in treating autoimmune diseases, cancer, and infectious diseases; and the high number of ongoing clinical trials. More than 360 clinical trials focusing on CAR-T and other cell-based therapies are being studied to interpret the potential of these therapies for treating various disease indications. The allogeneic cell therapy manufacturing services segment is anticipated to register a higher CAGR during 2022–2030. Many regenerative therapeutic applications have gained approval for clinical trials in the US and Europe due to the effectiveness of allogeneic stem cell therapeutics. With such approvals and the subsequent launch of new product lines, the demand for stem therapy using allogeneic stem cell therapeutics has increased in recent years. For instance, Alofisel, developed by TiGenix (Takeda), is the first allogeneic stem cell-based therapy that received marketing authorization in Europe to treat complex perianal fistulas in Crohn’s disease.

    In terms of region, North America is the fastest-growing region in the cell and gene therapy manufacturing services market. The US holds the largest market share of the cell and gene therapy manufacturing services market in the region.

    Thermo Fisher Scientific Inc, Merck KGaA, Charles River Laboratories International Inc, Lonza Group AG    

    WuXi AppTec Co Ltd, Catalent Inc., Takara Bio Inc., Nikon Corp, FUJIFILM Holdings Corp, National Resilience Inc, and Oxford BioMedica Plc. are among the key companies operating in the cell and gene therapy manufacturing services market.  

     [AT1]Recheck this timeframe.

    Contact Us
    Contact Person: Sameer Joshi
    Phone: +1-646-491-9876
    Email Id: sales@premiummarketinsights.com

    Get Free Sample PDF

    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Have a Question?


    Recent Posts